Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval
July 01 2019 - 1:00AM
NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL
STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN
MARKET APPROVAL
- Recently appointed Chief Medical Officer (CMO) Edwina
Baskin-Bey, M.D., will join the Executive Board
- Anne-Juliette Hermant, M.A., will be appointed Chief
People Officer (CPO) and will join the Executive
Board
- Former CMO Elsa Borghi, M.D., will lead innovation and
drug discovery for the company while leaving the Executive Board to
focus on her new responsibilities
- Chief Business Officer (CBO) Bernd Muehlenweg, Ph.D.,
will step down from the Executive Board and exit the
company
- Patrick Tricoli, Pharm.D. M.B.A., will remain CEO of
Nanobiotix Corp, the company’s U.S. affiliate, and also take on a
new role as the Global Head of Business Development
- Brandon Owens will be appointed Vice President (VP) of
Strategic Marketing and Corporate Communications
“As we enter our next stage as a company after
receiving our first European market approval for Hensify® (NBTXR3)
in Soft Tissue Sarcoma, we feel it is necessary to ensure we are
optimally structured for continued success. As such, we are
delighted to welcome our newcomers and congratulate those stepping
into new roles. I also want to personally thank Dr. Bernd
Muehlenweg, without whom we never would have achieved the business
successes we have realized to this point. We are in a new era at
Nanobiotix and I am confident these changes will serve to
accelerate our growth.” – Laurent Levy, CEO of
Nanobiotix
Paris, France and Cambridge,
Massachusetts, USA, July 1, 2019 –
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage
nanomedicine company pioneering new approaches to the treatment of
cancer, today announced organizational changes to align with
strategic priorities post European market approval for Hensify®
(NBTXR3). The changes aim to reinforce necessary competencies as
strategic priorities evolve, and to help accelerate the company’s
longstanding mission to significantly improve outcomes for
patients.
New C-level Appointments and Executive
Board MembersRecently appointed CMO Dr. Edwina Baskin-Bey
will join the Executive Board. Ms. Anne-Juliette Hermant will be
appointed CPO and will join the Executive Board as well.
C-level and Executive Board
DeparturesAs mentioned in a previous press release, former
CMO Dr. Elsa Borghi will leave the Executive Board to take on a new
function leading innovation and drug discovery. CBO Dr. Bernd
Muehlenweg will step down from the Executive Board and exit the
company.
New Management Appointments and
ResponsibilitiesDr. Patrick Tricoli will remain CEO of
Nanobiotix Corp, the company’s U.S. affiliate, while also taking on
a new role as Global Head of Business Development. Mr. Brandon
Owens will join Nanobiotix as its newly appointed VP of Strategic
Marketing and Corporate Communications.
Newcomer Biographical
Details
Ms. Anne-Juliette
HermantAnne-Juliette Hermant brings over 14 years of
experience in HR, talent management and development, acquired
across various entities at AXA. Ms. Hermant worked at AXA Partners
for 3 years as Global Head of Talent, Development, Culture and
Corporate Responsibility.
Before AXA Partners, Anne-Juliette served as
Chief Learning Officer of the AXA Group and was the Founder and
Head of the AXA Research Fund, a €100 million fund created by the
AXA Group to support frontier science in all fields related to an
understanding of the risks faced by human society.
Anne-Juliette was born in Strasbourg, France and
grew up between the French overseas territories of Guyane,
Martinique and Guadeloupe. She relocated to Lyon and then to Paris
to pursue her studies and has remained in the city throughout her
career.
Anne-Juliette graduated from the Ecole Normale
Supérieure and studied Politics at Sciences Po Paris. She holds an
Agregation and an M.A. in French literature.
Mr. Brandon OwensBrandon Owens
is a career communications professional that most recently
functioned as a Vice President on the Citigroup account at Publicis
New York. Mr. Owens was responsible for Citi’s global reputation
management communications and focused on integrated campaigns meant
to influence policy decisions relevant to banking in over 100
different countries.
Prior to Publicis, Brandon worked at agencies in
both New York and Chicago, leading accounts including Procter and
Gamble, Verizon Wireless, and Diageo.
Originally, Brandon comes from the Washington,
D.C. area of the United States. After starting his career in sales
for a small software firm in Baltimore, Maryland, he moved to
Chicago to begin his career in advertising. From there he moved to
New York City where he presently resides.
Brandon received his B.S. in Business from the
Robert H. Smith School of Business at the University of
Maryland.
-Ends-
About
NANOBIOTIX: www.nanobiotix.com
Incorporated in 2003, Nanobiotix is a leading,
clinical-stage nanomedicine company pioneering new approaches to
significantly change patient outcomes by bringing nanophysics to
the heart of the cell.
The Nanobiotix philosophy is rooted in designing
pioneering, physical-based approaches to bring highly effective and
generalized solutions to address unmet medical needs and
challenges.
Nanobiotix’s first-in-class, proprietary lead
technology, NBTXR3, aims to expand radiotherapy benefits for
millions of cancer patients. Nanobiotix’s Immuno-Oncology program
has the potential to bring a new dimension to cancer
immunotherapies.
Nanobiotix is listed on the regulated market of
Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg:
NANO: FP). The Company’s headquarters are in Paris, France, with a
U.S. affiliate in Cambridge, MA, and European affiliates in Spain
and Germany.
Contacts
Nanobiotix |
Communications Department+33 (0)1 40 26 07
55+1 (617) 852-4835contact@nanobiotix.com |
Investor Relations
Department+33 (0)1 79 97 29 99+1 (646)
241-4400investors@nanobiotix.com |
Media relations |
France - Springbok
ConsultantsMarina Rosoff+33 (0)6 71 58 00
34marina@springbok.fr |
|
United States –
RooneyPartners Marion Janic +1
(212) 223-4017mjanic@rooneyco.com |
|
Disclaimer
This press release contains certain
forward-looking statements concerning Nanobiotix and its business,
including its prospects and product candidate development. Such
forward-looking statements are based on assumptions that Nanobiotix
considers to be reasonable. However, there can be no assurance that
the estimates contained in such forward-looking statements will be
verified, which estimates are subject to numerous risks including
the risks set forth in the reference document of Nanobiotix
registered with the French Financial Markets Authority (Autorité
des Marchés Financiers) under number R.19-018 on April 30, 2019 (a
copy of which is available on www.nanobiotix.com) and to the
development of economic conditions, financial markets and the
markets in which Nanobiotix operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Nanobiotix or not currently considered
material by Nanobiotix. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or
achievements of Nanobiotix to be materially different from such
forward-looking statements.
Nanobiotix (EU:NANO)
Historical Stock Chart
From Apr 2024 to May 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From May 2023 to May 2024